Document is current
Any future updates will be listed below
-
Authors
Chowdhury, Adnan
Morgat, Clément
Bailly, Clement
Sunderland, John
Graves, Stephen A.
Scott, Andrew M.
Baker, Sean
Holman, Beverley F.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03849118 at ClinicalTrials.govDocuments that mention this clinical trial
Results from phase 3 study of <sup>89</sup>Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma (ZIRCON).
https://doi.org/10.1200/jco.2023.41.6_suppl.lba602
Radiation protection considerations with [89Zr]Zr-girentuximab PET and surgery
https://doi.org/10.1186/s13550-025-01247-1
<sup>89</sup>Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma: Results from phase 3 ZIRCON study.
https://doi.org/10.1200/jco.2023.41.16_suppl.4554
- License Information
-
More Information
Article History
Received: 4 October 2024
Accepted: 25 April 2025
First Online: 23 May 2025
Declarations
:
: The conduct of the ZIRCON clinical trial met all local, legal, and regulatory requirements. The trial was conducted in accordance with ethical principles originating in the Declaration of Helsinki and the International Conference on Harmonization (ICH) guideline E6: Good Clinical Practice (GCP). Patients provided written informed consent.
: Not applicable.
: C.M. received funding from Telix Pharmaceuticals but outside the scope of this study. C.B. has served on an advisory board for Telix Pharmaceuticals. A.M.S. has received funding from Telix Pharmaceuticals for research projects and clinical trials (to Institution), was a site Investigator of the ZIRCON study, and has served on advisory boards for Telix Pharmaceuticals (non-compensated).
